Evidence map›Paper›PMID 40827389›Full record

ArticleFuture medicinal chemistry2025

The role of descriptors extracted from ligand-target interaction to improve conventional QSAR model performance in the realm of angiogenesis receptor modulation to fight cancer.

Mohammadreza Torabi, Soroush Sardari, Horacio Pérez-Sánchez, Fahimeh Ghasemi

Abstract read
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohammadreza TorabiDepartment of Medical Biotechnology, School of advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-1938-3569
Soroush SardariDrug Design and Bioinformatics Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.ORCID 0000-0003-2080-7402
Horacio Pérez-SánchezStructural Bioinformatics and High-Performance Computing Research Group (BIO-HPC), Computer Engineering Department, Universidad Católica de Murcia (UCAM), Murcia, Spain.ORCID 0000-0003-4468-7898
Fahimeh GhasemiDepartment of Medical Biotechnology, School of advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-9333-4699

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study aims to develop a receptor-dependent 4D-QSAR model to overcome key limitations of traditional QSAR, including its dependency on molecular alignment and poor performance with small datasets, by integrating ligand - target interaction information. MATERIALS &

methodsAngiogenesis-related receptors, including VEGFR2, FGFR1-4, EGFR, PDGFR, RET, and HGFR (MET) were chosen based on the biological relevance in cancer. Ligand datasets with known IC₅₀ values were extracted from PubChem. One hundred docked conformers per ligand were generated using AutoDock. Protein - ligand interaction fingerprints were computed and encoded as 4D-descriptors. After evaluation via multiple classification algorithms, Random Forest was selected for model construction.

resultsThe results shown that the proposed model outperformed traditional 2D-QSAR approaches across all targets. Accuracy exceeded 70% in most datasets, including those with fewer than 30 compounds. Besides, the model performance was significantly improved via using all conformers versus using a single best pose. The model demonstrated robust predictive power across varying receptor classes under consistent assay conditions.

conclusionsThe proposed receptor-dependent 4D-QSAR model provides enhanced accuracy and generalizability for small, diverse datasets. Its integration of LTI-derived descriptors makes it a valuable tool for early-stage lead optimization and supports rational multi-target drug design in oncology.

Indexed as

Angiogenesis InhibitorsAntineoplastic AgentsNeoplasmsQuantitative Structure-Activity RelationshipAngiogenesisHumansLigandsMolecular Docking SimulationVascular Endothelial Growth Factor Receptor-2Angiogenesis InhibitorsAntineoplastic AgentsLigandsVascular Endothelial Growth Factor Receptor-2angiogenesis receptorsartificial intelligenceLigand–target interactionmachine learningreceptor-dependent 4D-QSAR

Identifiers

PMID40827389
PMCPMC12380209

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.